{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.8"},{"groupId":"OG001","value":"15.5"}]}],"title":"Very good (Core) [N=113,110]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.8"},{"groupId":"OG001","value":"30.0"}]}],"title":"Good (Core) [N=113, 110]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.5"},{"groupId":"OG001","value":"32.7"}]}],"title":"Fair (Core) [N= 113, 110]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1"},{"groupId":"OG001","value":"14.5"}]}],"title":"Poor (Core) [N= 113, 110]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8"},{"groupId":"OG001","value":"7.3"}]}],"title":"Very poor (Core) [N=113, 110]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.7"},{"groupId":"OG001","value":"27.8"}]}],"title":"Very Good ( 24 weeks) [N=87, 79]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.6"},{"groupId":"OG001","value":"50.6"}]}],"title":"Good (24 weeks) [N=87, 79]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7"},{"groupId":"OG001","value":"17.7"}]}],"title":"Fair (24 weeks) [N=87, 79]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"3.8"}]}],"title":"Poor (24 weeks) [N=87, 79]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}],"title":"Very Poor (24 weeks) [N=87, 79]"}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"115"}],"units":"Participants"}],"description":"The study physician made a global assessment of the patient's response to treatment using a 5-point Likert scale: Very good, good, fair, poor, very poor. The percentage of patients in each category is reported. The physician completed the assessment without viewing any of the patient's assessments (pain intensity \\[Visual Analog Scale and Likert scale\\] and patient's global assessment of response to treatment).","groups":[{"description":"Patients received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.\n\nAfter completing the first extension study, patients were offered to enter the second extension study, whereby all patients were treated open-label \"on demand\" with canakinumab 150 mg sc upon new flare for 1 year for a total duration of 18 months following randomization in the core study.","id":"OG000","title":"Canakinumab 150 mg"},{"description":"Patients received 1 intramuscular (im) injection of triamcinolone acetonide 40 mg and 1 subcutaneous (sc) injection of placebo to canakinumab on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 week extension study for any new gout flare on demand with the same treatment as assigned in the core study.\n\nPatients under this arm who agreed to continue to 2nd extension period of 12 months, were switched to canakinumab 150 mg sc for any new gout flare during this period","id":"OG001","title":"Triamcinolone Acetonide 40 mg"}],"paramType":"NUMBER","populationDescription":"The Full Analysis Set (FAS) consisted of all patients as randomized in the core study who had taken at least one dose of study drug. 'N' in each category indicates participants with observations analyzed for this endpoint at specified time points.","reportingStatus":"POSTED","timeFrame":"72 hours post-dose (randomization), 72 hours post-dose for the last post-baseline flare (during 24 weeks overall)","title":"Physician's Global Assessment of Response to Treatment","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}